miR-31、miR-21和miR-155在弥漫大B细胞淋巴瘤中的表达及意义

Significance of mi R-31,mi R-21 and mi R-155 expression in diffuse large B-cell lymphoma

目的分析mi R-31、mi R-21和mi R-155在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中的表达水平,并探讨其与DLBCL临床病理特征的关系。方法采用实时荧光定量聚合酶链反应(real-time quantitativepolymerase chain reaction,RT-PCR)检测92例DLBCL患者和84例对照mi R-31、mi R-21和mi R-155的表达水平,间期荧光原位杂交技术分析患者MYC和p53基因的异常情况,根据Hans的分类方法分为生发中心B细胞型(germinal center Bcell type,GCB型)和非生发中心B细胞型(non-GCB型)。结果 DLBCL组mi R-31、mi R-21及mi R-155表达水平高于对照组(P<0.05),mi R-31、mi R-21及mi R-155在non-GCB型的表达高于GCB型(P<0.05)。与MYC基因没有发生重排的患者相比,mi R-31、mi R-21及mi R-155在MYC重排的患者中表达下调(P<0.05)。mi R-31、mi R-21及mi R-155在p53基因丢失组的表达较基因正常组下调(P<0.05)。BCL-2蛋白阳性组mi R-31、mi R-21及mi R-155的表达较BCL-2蛋白阴性组下调(P<0.05)。Kaplan-Meier生存分析显示,mi R-31、mi R-21及mi R-155高表达的DLBCL患者生存率低于低表达的患者(P<0.05)。应用单因素和多因素Cox模型分析,发现mi R-31、mi R-21及mi R-155表达水平、免疫分型、p53基因与预后差异有统计学意义(P<0.05)。结论 mi R-31、mi R-21和mi R-155对DLBCL的诊断分型及预后判断有一定的参考价值,有望成为DLBCL治疗的新靶点。

Objective To analyze the expression levels of mi R-31,mi R-21 and mi R-155 in diffuse large B celllymphoma（DLBCL） and to investigate its relationship with clinicopathological features of DLBCL. Methods The expressionlevels of mi R-31,mi R-21 and mi R-155 were detected by real-time quantitative polymerase chain reaction（RT-PCR） in 92 patients with DLBCL and 84 healthy controls. Analysis of abnormal MYC and p53 genes in patients by interphase fluorescencein situ hybridization.According to the classification method of Hans,the germinal center,B cell type（GCB type） and nongerminal center B cell type（non-GCB type）, were divided into two types. Results The expression levels of mi R-31, mi R-21 and mi R-155 in DLBCL group were significantly higher than those in control group（P0.05）,and the expression of mi R-31,mi R-21 and mi R-155 in type non-GCB was significantly higher than that in type GCB（P0.05）. Compared with patients withno rearrangement of the MYC gene, mi R-31, mi R-21, and mi R-155 were significantly down regulated in patients with MYC rearrangement（P0.05）. The expression of mi R-31, mi R-21 and mi R-155 in the p53 gene loss group was significantly lowerthan that in the normal gene group（P0.05）. The expression of mi R-31, mi R-21 and mi R-155 in BCL-2 positive group wassignificantly lower than that in BCL-2 negative group（P0.05）. Kaplan-Meier survival analysis showed that the survival ratesof DLBCL patients with high expression of mi R-31, mi R-21 and mi R-155 were significantly lower than those of patients withlow expression of mi R-31, mi R-21 and mi R-155（P0.05）.Single factor and multi factor Cox model analysis showed that theexpression levels of mi R-31, mi R-21 and mi R-155, immunophenotype, p53 gene and prognosis were statistically significant（P0.05）. Conclusion Mi R-31,mi R-21 and mi R-155 have some reference value for the diagnosis, typing and prognosis ofDLBCL,and are expected to be a new target for DLBCL treatment.